SCHEMBL7234615

SCHEMBL7234615

O=C(O)c1cc(S(=O)(=O)Cl)c2ccccc2c1O

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 17/20 0.71
HSD17B10 Q99714 3/20 0.71
CYP2C9 P11712 2/20 0.71
HPGD P15428 2/20 0.60
KDM4E B2RXH2 1/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPT P10636 1/20 0.60
PKM P14618 1/20 0.60
HTT P42858 1/20 0.60
KMT2A Q03164 1/20 0.60
THRB P10828 1/20 0.59
TSHR P16473 1/20 0.59
ALOX12 P18054 1/20 0.59
ATIC P31939 1/20 0.59
BCL2L1 Q07817 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29539793 1.00 MCL1 (0.71) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL1808593 0.85 MCL1 (0.73) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL590115 0.83 MCL1 (0.71) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL589651 0.83 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL2789013 0.82 MCL1 (0.69) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL181076 0.80 MPL (0.45) MCL1HSD17B10CYP2C9HPGDKDM4E
SCHEMBL18392411 0.80 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL30076571 0.80 MCL1 (1.00) MCL1HSD17B10CYP2C9HPGDTHRB
SCHEMBL30076624 0.78 MCL1 (0.85) MCL1BCL2L1
SCHEMBL9110910 0.78 MCL1 (0.54) MCL1HSD17B10CYP2C9HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220396549-A1 SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF UNIV MARYLAND (US) 2022-12-15 US disclosed
EP-3319938-B1 SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF UNIV MARYLAND (US) 2022-04-06 EP disclosed
US-10858316-B2 Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-12-08 US disclosed
US-10858316-B2 Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-12-08 US disclosed
US-20180208554-A1 Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof UNIVERSITY OF MARYLAND, BALTIMORE 2018-07-26 US disclosed
US-20180208554-A1 Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof UNIVERSITY OF MARYLAND, BALTIMORE 2018-07-26 US disclosed
WO-2017011323-A1 SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEREOF UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-01-19 WO disclosed
US-6541491-B1 Treating ras mediated diseases, especially cancer. ZENECA LIMITED (GB) 2003-04-01 US disclosed
CN-1101380-C 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors ZENECA LTD (GB) 2003-02-12 CN disclosed
CN-1377647-A 4-mercaptopyrrolidinyl derivative as fernesyl transferase inhibitor ZENECA LTD (GB) 2002-11-06 CN disclosed
US-6232338-B1 4-Mercaptopyrrolidine derivatives as farnesyl transferase inhibitors ZENECA LIMITED (GB) 2001-05-15 US disclosed
CN-1197453-A 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors ZENECA LTD (GB) 1998-10-28 CN disclosed
EP-0842151-A1 4-MERCAPTOPYRROLIDINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1998-05-20 EP disclosed
WO-1997006138-A1 4-MERCAPTOPYRROLIDINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS ZENECA LIMITED (GB) 1997-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396549-A1 SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF MCL1, TP53, MYC MCL1 1/4885HSD17B10 4280/4885CYP2C9 4854/4885
US-10858316-B2 Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof MCL1, BCL3, BCL9 MCL1 1/4885HSD17B10 3795/4885CYP2C9 4851/4885
US-20180208554-A1 Small Molecule Inhibitors of the MCL-1 Oncoprotein and Uses Thereof MCL1, BCL3, BCL9 MCL1 1/4885HSD17B10 3795/4885CYP2C9 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.